Pfizer loses bid to reup Lipitor patent
From Times Wire Services
Pfizer Inc. has lost a preliminary bid to gain reissuance of one of the U.S. patents protecting its Lipitor cholesterol medicine.
Should the ruling stand, Pfizer would face U.S. generic competition to Lipitor, the world’s top-selling drug, in March 2010 rather than in June 2011.
Pfizer’s sales for Lipitor were $12.9 billion last year, including $7.8 billion in the U.S.
